The quantitative blood flow fraction (QFR) measurement system independently developed by the research team of Shanghai Jiaotong University has recently been approved by the State Drug Administration and became the first nationally certified non-guided blood flow reserve fraction (FFR) technology. Recently, the system has launched clinical applications in Beijing. Compared with the current clinically used coronary angiography diagnostic method, the accuracy of QFR diagnosis of myocardial ischemia increased by 33%. Experts believe that this major original technological breakthrough in the field of coronary heart disease diagnosis in China is expected to become the "new standard" for the diagnosis technology of coronary heart disease in the world. It is expected to significantly reduce the medical expenses of coronary heart disease and improve the prognosis of patients.
"At present, the intervention of coronary heart disease faces an important problem, that is, what lesions should be treated, and what lesions should not be treated." Academician Gao Runlin, academician of the Chinese Academy of Engineering and chairman of the National Committee of Cardiovascular Diseases, said that a large number of studies have revealed whether the lesions cause myocardial ischemia. It is an important criterion for judging whether intervention is needed. At present, the accurate assessment tool for coronary heart disease is scarce, and accurate diagnosis and treatment has become a pain point in the industry.
Experts pointed out that the diagnosis and treatment of coronary heart disease has only focused on the narrowing of vascular anatomy from the past and entered the era of functional evaluation. FFR technology is recognized worldwide as the gold standard for coronary heart disease assessment, which reflects the degree of myocardial ischemia. However, the technology is currently monopolized by foreign countries, and the cost of one-time consumable pressure guide wire for surgery exceeds 10,000 yuan; the surgical procedure is complicated and requires injection of vasodilator drugs, which takes a long time and increases the patient's treatment risk, resulting in the technology in the world, especially in China. The application rate is only 1%, and most patients can only perform routine coronary angiography.
The QFR measurement system, jointly developed by Shanghai Jiaotong University and Bodong Medical Imaging Technology (Shanghai) Co., Ltd., is an FFR technology that does not require a guidewire and requires no additional surgery or drugs. It performs three-dimensional reconstruction and hemodynamic analysis of coronary arteries through image data to achieve rapid functional assessment of coronary lesions, especially for critical lesions and multivessel disease analysis. Previous international multi-center clinical studies have shown that the accuracy of QFR diagnosis is consistent with the current gold standard results, thus breaking the "Achilles' heel" of the pressure guide wire FFR. QFR has been certified by the European Union in 2017. (Reporter Tan Jia)
ZHEJIANG SHENDASIAO MEDICAL INSTRUMENT CO.,LTD. , https://www.sdsmedtools.com